ArticleBMB reports2024
VSTM2L is a promising therapeutic target and a prognostic soluble-biomarker in cholangiocarcinoma.
Jungwhoi Lee et al.PubMed ↗Full text ↗
No numbers read from the abstract.
3 papers cite it
this papercites it
ArticleBMB reports2024
Jungwhoi Lee et al.PubMed ↗Full text ↗
No numbers read from the abstract.